[Current views on migraine and anti-migraine preparations].
On the basis of comprehensive experimental and clinical research the authors defined a variety of migraine-related mechanisms and schemes of migraine-correction by drugs, which should be both of the vascular- and general-actions to ensure an effective medication.
Ignatov
Iu D
IuD
Skoromets
A A
AA
Amelin
A V
AV
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000639:Amitriptyline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008376:Maprotiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008784:Methysergide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D009154:Mutation; D010918:Pizotyline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012106:Research; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013565:Sympatholytics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000319:Adrenergic beta-Antagonists; D000639:Amitriptyline; D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D000928:Antidepressive Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003000:Clonidine; D005473:Fluoxetine; D007093:Imidazoles; D008376:Maprotiline; D008784:Methysergide; D010918:Pizotyline; D010919:Placebos; D011433:Propranolol; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013565:Sympatholytics; D014662:Vasoconstrictor Agents; C114333:3-(3,4,5-trimethoxybenzoyloximino)-8-methyl-8-azabicyclo(3,2,1)octane; C043482:moxonidine